This concept has been explored to enhance immune responses in hematopoietic cancers, whereby targeting STAT3 specifically in TLR9 expressing cancer cells can be achieved using CpG based delivery of silencing oligos results in growth inhibition of myeloma and myeloid leukemia [217,218]. Here, TLR9 is linked to cancer.